Bringing innovative therapies to market quickly is no easy task. Developers and manufacturers face mounting pressure to meet critical timelines, manage limited sample volumes, and navigate evolving regulatory expectations - all while maintaining the highest standards of safety. For cell and gene therapies (CGT), Cell Line Characterization studies, Live Biotherapeutic Products (LBP) and plasmid-based biologics, traditional testing methods can no longer keep pace.

Soon after the ICH Q5A(R2) guideline revision was introduced in November 2023, next-generation sequencing (NGS) emerged as a transformational technology. The Eurofins BioPharma Product Testing (BPT) network of laboratories employs NGS to deliver the accelerated, regulatory-accepted results you need.

The NGS services we have developed specifically meet the needs of modern biopharma development. We offer direct access to scientific and bioinformatics experts, providing data and insights to optimise your submissions, de-risk regulatory filings, and reach milestones faster. Our advanced instrumentation, deep sequencing sensitivity, and robust bioinformatics analysis  ensure that every project delivers critical data with accuracy, reliability, and speed.

Whether you need biosafety testing for plasmid products or adventitious agent detection in complex therapies, choosing Eurofins BPT for NGS will accelerate the journey from drug discovery to patient impact.